Zobrazeno 71 - 80
of 205
pro vyhledávání: '"Rodabe N. Amaria"'
Autor:
Michael T. Tetzlaff, Jonathan L. Curry, Phyu P. Aung, Rodabe N. Amaria, Doina Ivan, Priyadharsini Nagarajan, Tsetan Dolkar, Carlos A. Torres-Cabala, Victor G. Prieto, Celestine M Trinidad, Kelly C. Nelson
Publikováno v:
Journal of Cutaneous Pathology. 45:539-544
LL-37 is a naturally occurring 37-amino-acid peptide that is part of the innate immune system in human skin. Preclinical studies have showed that intra-tumoral injections of LL-37 stimulate the innate immune system by activation of plasmacytoid dendr
Autor:
Jianhua Zhang, Alexander J. Lazar, Michael A. Davies, Merry Chen, Fernando Carapeto, Andrew E. Aplin, Dzifa Y. Duose, Rodabe N. Amaria, P. Andrew Futreal, Gabriele Romano, Jessica L.F. Teh, Jennifer L. McQuade, Whijae Roh, Jennifer A. Wargo, David Zhang, Roger Liang, Pei Ling Chen, Lawrence N. Kwong, Jun Li, Mingguang Liu, Ping Song
Publikováno v:
Cancer Discovery. 8:556-567
Combined MEK and CDK4/6 inhibition (MEKi + CDK4i) has shown promising clinical outcomes in patients with NRAS-mutant melanoma. Here, we interrogated longitudinal biopsies from a patient who initially responded to MEKi + CDK4i therapy but subsequently
Autor:
Beth Chasen, Kelly C. Nelson, Priyadharsini Nagarajan, Jennifer A. Wargo, Rodabe N. Amaria, Adi Diab, Gregg A Staerkel, Jonathan L. Curry, Carlos A. Torres-Cabala, Michael T. Tetzlaff, Victor G. Prieto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxicities are a well-recognized si
Autor:
Isabella C. Glitza, Anthony Lucci, Michael K. Wong, Wen-Jen Hwu, Richard E. Royal, James P. Allison, Alexander J. Lazar, Alexandre Reuben, Scott E. Woodman, P.A. Futreal, Padmanee Sharma, Sapna Pradyuman Patel, Adi Diab, Patrick Hwu, Zachary A. Cooper, Christine N. Spencer, Courtney W. Hudgens, Rodabe N. Amaria, Michael A. Davies, Jeffrey E. Gershenwald, Haifeng Zhu, Michael T. Tetzlaff, Peter A. Prieto, Jeffrey E. Lee, Jennifer A. Wargo, Rosalind Mouton, Vancheswaran Gopalakrishnan, Jennifer L. McQuade, Elizabeth M. Burton, Merrick I. Ross, Lauren Simpson, Miles C. Andrews, Hussein Abdul-Hassan Tawbi, Khalida Wani, Sangeetha M. Reddy, Li Zhao, Roland L. Bassett, Janice N. Cormier
Publikováno v:
The Lancet Oncology. 19:181-193
Summary Background Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for
Autor:
Sarah B. Fisher, Ahsan Farooqi, Merrick I. Ross, B.A. Guadagnolo, Priyadharsini Nagarajan, Rodabe N. Amaria, Jeffrey E. Gershenwald, Devarati Mitra, M.A. Davies, P. Krishna Rao, Andrew J. Bishop, Jennifer A. Wargo, Emily Z. Keung
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e60
Purpose/Objective(s) Anorectal melanoma (ARM) is a rare malignancy with poor outcomes. We analyzed our 30-year experience using sphincter-sparing local excision (SSLE) and adjuvant radiation therapy (RT) to optimize local control (LC) across eras of
Autor:
Marie-Andree Forget, Min Zhang, Rina M. Mbofung, Ashish Kalra, Timothy P. Heffernan, R. Eric Davis, Trang N. Tieu, Weiyi Peng, Florian L. Muller, Seram Devi, Cara Haymaker, Patrick Hwu, Chantale Bernatchez, Chengwen Liu, Soraya Zorro Manrique, Anil K. Sood, Chunyu Xu, Leila Williams, Nikunj Satani, Jodi A. McKenzie, Shruti Malu, Rodabe N. Amaria, Sunila Pradeep, Yuan Chen, Emily Ashkin, Lu Huang, Jason Roszik, Jianhua Hu
Publikováno v:
JNCI Journal of the National Cancer Institute
Background Immunotherapy has increasingly become a staple in cancer treatment. However, substantial limitations in the durability of response highlight the need for more rational therapeutic combinations. The aim of this study is to investigate how t
Autor:
Rodabe N. Amaria, Meredith Ann McKean
Publikováno v:
Clinical Skin Cancer. 2:32-38
Treatment strategies in metastatic melanoma have attempted to use the immune system to target cancer since the 1980s. Adoptive cell transfer using autologous tumor-infiltrating lymphocytes (TILs) extracted from a patient tumor and cultured in vitro w
Autor:
Rodabe N. Amaria, Beate C. Litzenburger, Funda Meric-Bernstam, Mark J. Routbort, Amber Johnson, Cathy Eng, John Mendelsohn, Yekaterina B. Khotskaya, Lauren Brusco, Elmer V. Bernstam, Vijaykumar Holla, Kenna R. Mills Shaw, Jia Zeng, Nora S. Sanchez, Ann Marie Bailey, Chetna Wathoo, Gordon B. Mills, Bryan K. Kee
Publikováno v:
Cancer. 124:966-972
BACKGROUND Genomic testing is increasingly performed in oncology, but concerns remain regarding the clinician's ability to interpret results. In the current study, the authors sought to determine the agreement between physicians and genomic annotator
Autor:
Leon Chen, Marc Uemura, Genie A. Landon, Rodabe N. Amaria, Amir A. Jazaeri, Phyu P. Aung, Carlos A. Torres-Cabala, Adrienne N. Choksi, Priyadharsini Nagarajan, Brinda Rao Korivi, Michael A. Davies, Padmanee Sharma, Michael T. Tetzlaff, Jonathan L. Curry, Victor G. Prieto, Adi Diab
Publikováno v:
Journal of Cutaneous Pathology. 44:1080-1086
Immunotherapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1) have showed substantial therapeutic benefit in patients with clinically advanced solid malignancies.
Autor:
Jennifer L. McQuade, Michael K.K. Wong, Charlotte E. Ariyan, Hussein Abdul-Hassan Tawbi, Elizabeth M. Burton, Sarah B. Fisher, Michael A. Postow, Sapna Pradyuman Patel, Adi Diab, Emily Z. Keung, Denái R. Milton, Michael A. Davies, Isabella C. Glitza, Jennifer A. Wargo, Rodabe N. Amaria, Merrick I. Ross, Lauren Simpson, Michael T. Tetzlaff, Ryan P. Goepfert, Jeffrey E. Gershenwald
Publikováno v:
Journal of Clinical Oncology. 39:9502-9502
9502 Background: Neoadjuvant therapy (NT) for pts with clinical stage III melanoma remains an active area of research interest. Recent NT trial data demonstrates that achieving a pathologic complete response (pCR) correlates with improved relapse-fre